Market Research Blog

Future Market Insights (FMI) has published a new research report on vulvodynia treatment market growth. The report has been titled, “Vulvodynia Treatment Market: Global Industry Analysis 2013 – 2021 and Opportunity Assessment 2022 – 2028.”  The report states that a recent Harvard study showed that there are approximately 6 million American women who are suffering from vulvodynia. Over 60% of patients’ report of visiting three or more health care providers for diagnosis and an astonishing 40% of patients remain undiagnosed. This study also reported that 40% of women with painful symptoms did not even seek medical care. Associations such as the National Vulvodynia Association (NVA) are playing a vital role in spreading awareness regarding Vulvodynia treatment. The NVA announced the launch of “Indivisible: Breaking the Silence”, a campaign empowering women with vulvodynia to break their silence and improve the path to diagnosis and treatment. According to the report, the global vulvodynia treatment market is expected to register a CAGR of 6.3% over the forecast period of 2022 and 2028. The market was worth US$ 4,261.2 Mn in 2021 and is expected to rise to a valuation of US$ 8 Bn by the end of 2028.

In order to cater to the need of the growing number of patients, companies are looking out for treatments and drugs that can subside the pain related to vulvodynia. Towards this, they are investing in research and development and mergers and acquisitions. For instance, in January 2016, Merck & Co. Inc., acquired IOmet Pharma Ltd., a privately held U.K.-based drug discovery company focused on the development of innovative medicines for the treatment of cancer. The other leading companies operating in the market are Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc., and Allergan plc, among others.

Growing Adoption to Augur Well for Global Market Revenue Growth

The swelling number of patients suffering from vulvodynia and harsh nature of chronic vulvar pain have led to the adoption of early diagnosis and treatment. The adequate results of medical treatments such as drugs, injections and creams have increased the preference for medication to treat vulvodynia. Furthermore, increasing adoption of medicinal treatments of vulvodynia has resulted in an increase in the sales of hormones, local anesthetics, and antidepressants. Additionally, promising compensation policies in most of the developed countries are also expected to act as a value driver to the growth of the global vulvodynia treatment market. On the other hand, the growing prevalence of the vulvodynia disease among women across the globe is a core factor that is pushing the growth of the vulvodynia treatment market. Vulvodynia is a very common disease in the United States and across the globe. Nevertheless, the ailment remains underdiagnosed or in some cases also incompetently treated.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-4985

Lethargic Research and Development for Vulvodynia Treatment Drugs to Slow Down Market Growth

Owing to the absenteeism of detailed information by patients, ignorance of the cause of vulvar pain, and satisfactory results of anticonvulsants and tricyclic antidepressants, researchers are unable to unveil the exact cause of vulvodynia and thereby the R&D on vulvodynia drugs is limited. After anticonvulsants and tricyclic antidepressants, only serotonin and norepinephrine reuptake inhibitors (SNRIs) drugs have showed positive results. Furthermore, if observed, the research and development for vulvodynia treatment is also in a very sluggish phase.

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
  • Detailed insights of market segments and sub-segments for historical as well as forecast period
  • A competitive analysis of prominent players and emerging players in the keyword market
  • Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-4985

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global on-site preventive care market size is expected to witness a CAGR of 7.1% from 2022 to 2028. The market was worth around US$ 16,135 Mn in 2022 and is likely to touch a valuation of US$ 32,063 Mn approximately by the end of 2028.

The report states that the standards set in the workplace for the safety of workers and the need to adhere to workplace norms have triggered the demand for on-site preventive care. Moreover, the increasing incidences of workplace illness has also made it an obligation for employers to follow employee safety codes and adopt on-site preventive care.

On-site clinics enable employees to receive the required essential care at the time of emergency without having to leave the workplace. The clinicians in these clinics also aid employees in searching for a primary care physician who they can consult with on a regular basis. As a Future Market Insights analyst quotes, “Changes in lifestyle among the working class have incessantly impelled employers to establish certain behavioural standards within the workplace. This is one of the core factors responsible for the growing adoption of on-site preventive care in several organisations across the globe.”

North America and Western Europe to Compete Neck and Neck

In 2017, North America held a share of 37.0% in the global on-site preventive care market closely trailed by Western Europe. The dominance of North America can be attributed to the several policies implemented by the U.S. government pertaining to employee safety and the adoption of certain employee codes of safety. The U.S. is also an extremely mature market owing to the high adoption of workplace wellness programmes.

Burgeoning Penetration of Workplace Wellness Programmes to Bode Well for the Market

In the recent past, workplace wellness programmes have earned the merit of being one of the most adopted healthcare services in the world. It has been further expected that its adoption will increase in the coming years owing to the implementation of the Affordable Care Act. This act is expected to promote an increase in the employee-based coverage of workplace wellness and also promote these programmes through several provisions. Moreover, the growing incidences of chronic diseases among the working population have also become a matter of concern and this has compelled employers across the globe to adopt as well as promote workplace wellness programmes.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-5518

Furthermore, employers who have adopted on-site preventive care services have reported enhanced performance ranging from heightened morale and cost savings to productivity. The death of time, access, and cost along with misunderstanding of the benefits of prescribed wellness programmes result in the underutilisation of primary care services. As a result, employees flood emergency rooms, missing out on critical preventive care measures and also leave chronic conditions go unmanaged. In this regard, on-site clinics provide employees with the necessary support without having to leave their work and plus the clinicians also work together with the patients in a cohesive environment to address their various health related issues.

Companies to Innovate Services in the Global Market

In order to stay ahead of the competition, several companies operating in the global market are focussing on innovating their existing services and integrating new services. Some of the leading companies in the market are Premise Health, OnSite Care, Inc., PrevMED, RepuCare, Healthcare Solutions Centers, LLC, McCormack & Kale Motiva Health & Chiropractic, Inc., Marino Wellness, Kinema Fitness, and TotalWellness.

Key Market Segments Covered in On-site preventive care Market Research

By Service Type

• Acute Care
• Chronic Disease Management
• Wellness and Coaching
• Nutrition Management
• Diagnostic and Screening
• Others

By Management Model

• In-house Management Model
• Hybrid Management Model
• Outsourced Management Model

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-5518

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

Future Market Insights’ recently compiled report offers prospects of the global molecular biology enzymes, kits & reagents market growth for the period between 2017 and 2026. The report projects the market to register a splendid growth through 2026. Sales of molecular biology enzymes, kits & reagents worldwide are poised to exceed US$ 22,000 Mn in revenues by 2026-end.

Technological Advancements Leading to Enhanced Efficiency & Greater Precision of Molecular Biology Enzymes, Kits & Reagents

Many technological advancements are been made by the molecular biology enzymes, kits & reagents manufacturers, who dedicate their focus toward developing advanced products in a bid to enhance their product portfolio. The advanced products facilitate the research processes with offerings such as enhanced efficiency and greater precision. One of the greatest examples of this is SMART Digest Kit developed by Thermo Fisher Scientific, Inc., designed particularly for the biopharmaceutical & proteomic applications. This kit enables the generation of data of high quality, meanwhile curtailing time needed for preparation of samples. Adoption of molecular biology enzymes, kits & reagents will further be propelled by huge investments made in the research & development by pharmaceutical & biotechnology industries coupled with the provision of several reimbursements for molecular diagnostics.

A significant increase in the genetic disorders’ prevalence has been witnessed since the recent past, thereby driving adoption of molecular diagnostics. The processes of molecular diagnostics including epigenetics and polymerase chain reaction (PCR) require molecular biology enzymes, kits & reagents as, which form an integral part of these processes. Mounting cases of genetic disorders in light of growing geriatric population will significantly fuel demand for molecular biology enzymes, kits & reagents in the near future. Genetic data of individuals is considered highly confidential, and sharing this data is strictly prohibited. Genome sequencing aids identifying & treating a wide variety of diseases. However, there is lack of tools that are effective for securing the genetic information of individuals, and the information ends up being stored in cloud databases, which further poses threats regarding data thefts. The absence of effective technology to store genetic information is anticipated to negatively influence demand for molecular biology enzymes, kits & reagents.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-6385

Key Players :

• Jena Bioscience GmbH
• Takara Bio Inc.
• Roche Holdings Inc.
• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Promega Corporation
• KRISHGEN BioSystems
• Agilent Technologies Inc.
• Qiagen N.V.
• and Merck & Co Company.

Key Research Findings from the Report

• Although sequencing is expected to prevail as the largest application of molecular biology enzymes, kits & reagents in terms of revenues, synthetic biology is anticipated to persist as the fastest expanding application segment in the market. Cloning application segment will also exhibit an impressive expansion, and will account for the second largest revenue share of the market during the forecast period.
• Academic and research institutes are expected to register fastest expansion in the market through 2026, based on end-users. However, revenues from this end-user segment will remain comparatively lower than other end-user segments included in the report.
• Revenues from sales of molecular biology enzymes, kits & reagents for use in pharmaceutical and biotechnology companies are expected to account for the largest market share during 2017 to 2026.
• Kits & reagents will prevail as top-selling and fast-selling product in the market. Between modifying enzymes and restriction enzymes, the latter will exhibit a relatively faster sales expansion whereas the former will account for a larger market revenue share through 2026.
• North America is anticipated to remain the most remunerative market for molecular biology enzymes, kits & reagents, followed by Asia-Pacific excluding Japan (APEJ).

Prominent companies in the global molecular biology enzymes, kits & reagents market are implementing strategies including manufacturing capacity & geographic expansion. Manufacturers are also concentrating on new product launches for enhancing their shares in this increasingly competitive market. The report has listed key players supporting the market growth, which include Thermo Fisher Scientific Inc., Illumina, Inc., Roche Holdings, Inc., Takara Bio Inc., Jena Bioscience GmbH, Merck & Co Company, Qiagen N.V., Agilent Technologies, Inc., KRISHGEN BioSystems, and Promega Corporation.

Browse Full Report:

https://www.futuremarketinsights.com/reports/molecular-biology-enzymes-kits-reagents-market

Market Segments:

Region

• North America
• Latin America
• Europe
• Japan
• APEJ
• MEA

Product Type

• Kits & Reagents
• Modifying Enzymes
• Restriction Enzymes
• Other Product Types

End User

• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Centers
• Academic and Research Institutes
• Other End Users

Application

• Sequencing
• Cloning
• Polymerase Chain Reaction
• Restriction Digestion
• Synthetic Biology
• Epigenetics
• Other

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-6385

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global neuroendocrine carcinoma treatment market demand was valued US$ 1.7 Bn in 2022, and is expected to exhibit a CAGR of 8% during the forecast period (2019 – 2029).

Prominently driven by collaborative strategies for speedy research of drugs for neuroendocrine carcinoma treatment, the market is set for an impressive growth during the forecast period. Rising number of patients diagnosed with neuroendocrine carcinoma, increasing number of patients seeking treatment, and innovative drugs under clinical trials, along with research grants from government agencies are expected to boost the growth of the neuroendocrine carcinoma treatment market during the forecast period. In June 2019, Progenics Pharmaceuticals presented long-term follow up data from its pivotal phase 2 study of Azdera, which showed overall survival of 73.1% at two years and 44.2% at four years, improving the overall survival rate in patients suffering from neuroendocrine carcinoma.

 “Rising number of patients seeking treatment along with collaborative actions by manufacturers to provide novel treatment options, and increasing research grants for drug innovation are anticipated to boost neuroendocrine carcinoma treatment market growth during the forecast period.”

Key Players:

The key players are Pfizer Inc., Novartis AG, Chiasma Inc., Ipsen, Abbvie Inc., Valeant Pharmaceuticals International Inc., Jubilant Life Sciences Ltd., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Advanced Accelerator Applications, Mateon Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Isotopen Technologien München AGGlobal, Hutchison China MediTech Ltd, Amgen Inc, Celgene Corporation

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-1278

Key Takeaways of Neuroendocrine Carcinoma Treatment Market Study

• Owing to large patient pool seeking treatment for gastric neuroendocrine tumors, the segment is expected to dominate the neuroendocrine carcinoma treatment market.
• Somatostatin analog therapy for vasoactive intestinal peptide, carcinoid tumors, pituitary adenomas, and other indications is expected to gain traction over targeted therapy and chemotherapy during the forecast period.
• Hospitals remain prominent end users as compared to clinics, as hospitalization of patients is required to monitor the progress of therapy deployed during the treatment of neuroendocrine carcinoma.
• North America is expected dominate the global neuroendocrine carcinoma treatment market, owing to improved healthcare infrastructure, favorable reimbursement scenario, increasing research grants, and large target patient pool.

Neuroendocrine Carcinoma Drug Manufacturers Focusing on Collaborations to Gain Competitive Advantage

AbbVie Inc., Advanced Accelerator Applications, and F. Hoffmann-La Roche are among the leading manufacturers that operate in the neuroendocrine carcinoma treatment market. In December 2019, AbbVie and Scripps Research announced a collaboration to develop a broad range of new therapeutics in the areas of oncology, immunology, neurology, and fibrosis. This strategic move is expected to cater to the needs of patients by innovating refined novel medicines. Eisai’s Levinima was approved in combination with Novartis’s Afinitor for the treatment of advanced renal cell carcinoma, in May 2016. This collaboration agreement has set the terms, whereby the sales teams from both pharmaceutical companies will promote the availability of this combination regimen to health service providers. In November 2017, VBL Therapeutics and NanoCarrier Co., Ltd. signed an exclusive agreement for VB-111 for the development, commercialization, and supply of ofranergene obadenovec (VB-111) in Japan. In December 2018, Advanced Accelerator Applications entered into an exclusive option and license agreement with FUJIFILM Toyama Chemical Co. to develop and commercialize radiolabeled molecules for oncology indications.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-1278

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global diabetic macular edema (DME) market value is projected to register a sluggish expansion at 1.1% CAGR through 2027, according to a report by Future Market Insights (FMI). The report estimates the market to reach US$ 3710.2 Mn in 2017; by 2027 this number is expected to surpass US$ 4,100 Mn.

An Uptake of Intravitreal Implants by Patients to Drive Growth of the Market in North America

North America will remain dominant in the global diabetic macular edema market. An uptake of intravitreal implants by new as well as existing patients, who do not show any improvement post-treatment with intravitreal injections, is expected to sustain growth of the market in this region.

Although control of diabetes is a health priority in developed North American countries, such as the U.S., less attention is given to DME management, with diabetes-related caregivers tending to focus on treatment of diabetic complications. A major reason behind this is lack of effective treatment for DME in North America. In addition, an error exists between industry sponsored and independently run clinical trials. Most of the independent clinical trials for DME treatment lack long-term results pertaining to safety and efficacy of new combination therapies for DME. These factors are likely to inhibit growth of the market in North America.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-2697

Diabetic Macular Edema Market in Western Europe to Register the Highest CAGR through 2027

The diabetic macular edema market in Western Europe is expected to register a comparatively higher CAGR than other region segments through 2027. Pharmaceutical companies in this region are making substantial investments in research and development, new technologies, and infrastructure in order to capture a market share in the surging burden of eye diseases. This is expected to retain growth of the market in Western Europe.

However, patients in Western Europe resist the intake of intravitreal injections of anti-VEGF drugs, which leads to an instant increase in intraocular pressure causing severe pain in the head or eyes. This a major factor impeding growth of the diabetic macular edema market in Western Europe.

Anti-VEGF will Remain Preferred Product in the Global Diabetic Macular Edema Market

Anti-VEGF will remain preferred product in the market, with sales estimated to expand at 1% CAGR through 2027. Eylea will continue to be the most lucrative anti-VEGF drug in the market. However, demand for corticosteroids will remain comparatively lower than anti-VEGF during the forecast period.

By product form, intravitreal injections will continue to be sought-after in the market, with sales poised to surpass US$ 4,000 Mn by 2027-end. Sales of intravitreal implants will register a comparatively higher CAGR than intravitreal injections through 2027.

Hospital pharmacy is estimated to remain the largest distribution channel in the market, as majority of countries across the globe dispense intravitreal injections and implants to outpatients by hospital pharmacies. Retail pharmacy, which mainly provides aliquots of off-label indications such as Avastin prescription, will register a comparatively low CAGR than hospital pharmacy in the market through 2027.

Key market players identified in FMI’s report include Novartis AG, Bayer AG, Allergan Plc., F. Hoffman-La Roche Ltd., Alimera Sciences Inc., Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-2697

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global Portable Ultrasound Bladder Scanner Market share was valued at US$ 126.3 Mn in 2021 and is expected to reach US$ 191.7 Mn by 2028. As per the findings of a new Future Market Insights (FMI) report, the global portable ultrasound bladder scanner market will thrive on the back of rising adoption of non-invasive diagnostic procedures in urology imaging.

Advancements in ultrasound bladder scanner reduce the chance of catheter-associated urinary tract infection (CAUTI), reduce the time for operating procedures with no sonographer required, thus driving the growth of the portable ultrasound bladder scanner market during the forecast period. Distribution channels are well established for portable ultrasound bladder scanner due to increase in demand from end users such as hospitals, diagnostic centers, clinics and ambulatory surgical enters.

The key players in portable ultrasound bladder scanner market are C. R. Bard, Inc., Verathon Inc., SRS MEDICAL SYSTEMS INC, Laborie Medical Technologies Inc., Echo Son SA, Signostics Inc., dBMEDx Inc., Sonostar Technologies Co., Limited, Caresono Technology Co., Ltd, and GE Healthcare Inc.

Key Takeaways – Portable Ultrasound Bladder Scanner Market Study

• The market share of 3D portable ultrasound bladder scanner devices is evaluated to grow at a significant rate by the end of 2028, as it provides high-end accuracy for measuring bladder volumes during urodynamics, thus surpassing the market of 2D portable ultrasound bladder scanner.
• Sales of portable ultrasound bladder scanner are envisaged to be higher in the region of North America. The rising prevalence of urological diseases among women and increasing adoption of portable ultrasound bladder scanner for diagnosis application are few factors contributing to the growth of the portable ultrasound bladder scanner market in the region.
• Portable US bladder scanners can be moved and carried to any location as and when required, due to its compact structure. One of the primary factors driving the portable bladder ultrasound scanner market is the accuracy and easy to use in both adults and children.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-2008

Technological advancements and well-established distribution network will accelerate the growth of portable ultrasound bladder scanner market in the following years. Furthermore, deeper penetration of internet and rapid E-commerce expansion will significantly support the growth of portable ultrasound bladder scanner sales.

Portable Ultrasound Bladder Scanners Replacing Unnecessary Catheterization

Portable ultrasound bladder scanner has reduced the need for unnecessary catheterization, which also helps in the prevention of patients’ dignity and discomfort. Patients suffering from urological disorders opt for cardio portable ultrasound bladder scanner due to its less complex nature as compared to other diagnostic solutions. It also reduces the risk of catheter-associated urinary tract infection.

Such promising attributes facilitates the use of advanced portable ultrasound bladder scanners in hospitals, clinics, ambulatory surgical centers and others. Thus, enhanced patient care and addressing clinical challenges worldwide are expected to enhance demand for portable ultrasound bladder scanner during the forecast period.

Seeking More Information About Report Inclusions?

The portable ultrasound bladder scanner market, a new study from Future Market Insights, opines on the evolution of the portable ultrasound bladder scanner market from 2014 – 2021 and presents demand projections from 2022 – 2029 on the basis of product type (3D portable ultrasound bladder scanner, and 2D portable ultrasound bladder scanner), and end user (hospitals, diagnostic centers, clinics, and ambulatory surgical centers) in seven prominent regions.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-2008

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The Saudi Arabia pharmaceutical market size is estimated to be valued at US$ 5,209.5 Mn by 2016 end and is expected to expand at a CAGR of 9.0% over the forecast period (2016–2026). The significant rise in lifestyle-related diseases and the developments in healthcare infrastructure are expected to influence the demand for pharmaceuticals in Saudi Arabia. In 2016, the Saudi Arabia pharmaceutical market is anticipated to procure value worth US$ 5,209.5 Mn at a y-o-y growth of 6.0 % over 2015. The mounting demand for branded drug products will continue to incite the growth of the Saudi Arabian pharmaceutical market in 2016.

The demand for pharmaceuticals in Saudi Arabia is expected to register substantial growth owing to the increasing penetration of health insurance companies and the rising incidence rate of non-communicable diseases. Furthermore, the exceptional rise in the per capita income of Saudi Arabia is also expected to foster the demand for branded pharmaceutical drugs. Another key factor driving the growth of the pharmaceutical market in Saudi Arabia is the country’s strategic move to allow 100% FDI in the pharmaceuticals sector. Although, the shortage of profound indigenous research capacity in the pharmaceutical industry and the delayed registration of drug and medicine patents is expected to limit the expansion of the market in 2016 and beyond.

Based on the product type, the pharmaceutical market in Saudi Arabia is expected to witness an upsurge in the prescription-type branded drug products. In terms of market value, the branded drugs are estimated to reach US$ 2,760.8 Mn by 2016-end. The demand for generic drugs is projected to secure steady growth, attributing to the insisting promotion of generic drug adoption by healthcare insurance providers.

On the basis of the diseases, the pharmaceutical drugs used for treatment of cardiovascular diseases will continue exhibiting robust growth in 2016. The demand for cardiovascular medications will continue to surge due to the prominence of circulatory disorders in Saudi Arabia. Additionally, the rising prevalence of disorders related to body sugar levels is expected to make diabetes a rapidly growing disease-based sub-segment in the Saudi Arabia pharmaceutical market.

The pharmaceutical market in Saudi Arabia is also segmented on the basis of distribution channel, where retail pharmacies will continue to account for 80% market share compared to hospital pharmacies. The westernised modernisation of retail pharmacies in Saudi Arabia has led to the availability of a wide range drugs and medicinal products, thereby attaining a considerable growth in the retail pharmacy sub-segment in 2016 and further.

Get Sample PDF Brochure: 

https://www.futuremarketinsights.com/reports/sample/rep-gc-1733

The rising resource potential in Saudi Arabia is projected to positively reform the production environment for pharmaceutical manufacturers. In order to expand the market’s size, structuring alliances with well-established native companies is predicted to be a key strategy for global pharmaceutical leaders. The key players in the Saudi Arabia pharmaceutical market include Novartis AG, SPIMACO, Pfizer Inc., and Glaxosmithkline plc., Jamjoom Pharma,  and Tabuk Pharmaceutical Manufacturing Co. among others.

Long-term Outlook: The Saudi Arabia pharmaceutical market is expected to expand at a CAGR of 9.0% over the forecast period 2016-2026. In terms of market value, the pharmaceutical market in Saudi Arabia is estimated to be worth US$ 12,281.4 Mn by the end of forecast period.

Key Segments Covered

Product Type:

• Prescription Products
  • Branded Drugs
  • Generic Drugs
• Over The Counter (OTC) Products

Disease Type:

• Cardiovascular Diseases
• Diabetes
• Cancer
• Obesity
• Infectious Diseases
• Other Diseases

Distribution Channel:

•  Hospital Pharmacies
• Retail Pharmacies

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gc-1733

Table of Content

1. Research Methodology
2. Assumptions & Acronyms
3. Executive Summary
4. Saudi Arabia Pharmaceutical Market Overview

4.1. Definition

4.2. GCC Pharmaceutical Market Overview

4.3. Value Chain Analysis

4.4. Trade Associations and Trade Fairs

4.5. PESTLE Analysis

4.6. Saudi Arabia Pharmaceuticals Market Overview, 2015–2026

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gc-1733

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

Norovirus Infection Treatment Market Overview

Norovirus is the common viral infection which can affect anyone. It is a contagious infection can be spread through food or water and also by touching the contaminated surface. Norovirus infection leads to stomach pain, nausea, diarrhea and throwing up.

These symptoms are very serious, especially among older people and children. Norovirus infection also lead to fever, headache and body ache. Currently, there is no specific treatment available in the market to cure norovirus infection completely. Additionally, there is no vaccine available in the market for the prevention of norovirus infection.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6947

Oral intake of plenty amount of fluid may also cure the norovirus infection. But, for the people having severe nausea or vomiting during norovirus infection can be prescribed with the medicine by a physician to stop or reduce the vomiting. Intake of electrolyte powder is a common type of treatment option for norovirus infection which avoids the complication of dehydration.

Rather than go to physician clinics norovirus infection can also be cured by home remedied such as consumption of plenty amount of fluid or electrolyte.

Norovirus Infection Treatment Market: Drivers and Restraints

Increasing incidence of norovirus infection among people is the major factor driving the growth of norovirus treatment market. Moreover, life style habit of having junk food may also increase the chances for spreading of norovirus infection treatment.

Additionally, lesser consumption of potent water by the majority of population in under developing countries also leads to high risk of norovirus infection. The adoption of homemade remedies could hamper the growth of clinical treatment market for norovirus infection to some extent.

Lack of awareness among the people about the personal health hygiene & lack of awareness about the infection will also hamper the growth of norovirus infection treatment market.

Norovirus Infection Treatment Market: Overview

The global norovirus infection treatment is expected to show significant growth over the forecast period due to rising incidences of norovirus infection. NGO tends to aware the people about the personal hygiene to avoid getting infected from norovirus.

Electrolyte powder is the most common treatment option to cure the norovirus infection. Therefore, electrolyte powder segment is expected to dominate the revenue share by treatment type for global norovirus treatment market.

Among all distribution channel, retail pharmacies segment is expected to be most lucrative market over the forecast period through retail pharmacies is the first choice of people to buy electrolyte powder.

Norovirus Infection Treatment Market: Regional Overview

On the basis of regional presence, global norovirus infection treatment are classified into eight key regions – North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding China & Japan, China, Japan, and the Middle East & Africa.

Request for Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-6947

North America is the most lucrative market for norovirus infection treatment due to awareness among the people about the norovirus infection.  After North America, norovirus infection treatment market is then followed by Western Europe and Japan.

In APECJ region, India and Australia are the major markets for norovirus infection treatment due to rising incidences of norovirus infection in these countries. MEA and Latin America is expected to show relatively low adoption norovirus infection treatment owing to lack of personal hygiene among the people.

Norovirus Infection Treatment Market: Key Players

Examples of some of the market participants in norovirus infection treatment market identified across the value chain include Nimraj Chem Agrovet, B.F. Ascher & Company, Inc., Meda Pharmaceuticals Inc., Concordia Pharmaceuticals Inc., AvKare, Inc., Valeant Pharmaceuticals International, Inc., Capellon Pharmaceuticals, LLC. Water Life Technologys, Mizuno Pharmacies.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Norovirus Infection Treatment Market: Segmentation

The global Norovirus Infection Treatment Market is classified on the basis of treatment type, distribution channel, and region.

Based on application treatment type Treatment Market is segmented into following:

• Intravenous Fluid
• Antispasmodics
• Analgesics
• Antipyretics
• Electrolyte Powder

Based on distribution channel Norovirus Infection Treatment Market is segmented into following:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Top Related Reports Healthcare Market Insights

https://www.sbookmarking.com/story/orthobiologics-market-report-overview-with-geographical-segmentation-by-revenue-with-forecast-by-2027

https://medium.com/@vishal.tupkar/peptide-therapeutics-are-witnessing-substantial-demand-owing-to-increasing-application-in-the-b80bd01ed17e

https://www.evernote.com/shard/s703/client/snv?noteGuid=d4363a38-1164-35d1-845f-9e39c0bebe3f&noteKey=2ea430c112f1f4455caba379543744f9&sn=https%3A%2F%2Fwww.evernote.com%2Fshard%2Fs703%2Fsh%2Fd4363a38-1164-35d1-845f-9e39c0bebe3f%2F2ea430c112f1f4455caba379543744f9&title=Peptide%2BTherapeutics%2BMarket%2BFuture%2BScenario%252C%2BKey%2BInsights%252C%2BTop%2BCompanies%2B2025

https://www.tumblr.com/researchvishal/696542951080443904/peptide-therapeutics-market-revenue-worth-size?source=share&_branch_match_id=1092693908979658921&_branch_referrer=H4sIAAAAAAAAAwXBQQ7CMAwEwBe5ljjyGzesZIumCfamVLyeGSdnPVWNG1ffj9za6JooWDa%2FotwOnZiMF4SOtInFaCXd8g1K4sK5IN%2BRdKn4QT8t75sxYn%2FkHwfqcdFgAAAA

https://www.xing.com/discover/detail-activities/6719632270.c70c85

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs